News

Elan posted a net loss of $43.6m for the third quarter 2010, or $0.07 loss per diluted share, compared to net income of $52.3m, or $0.11 per diluted

Mylan has posted net earnings of $108.42m for the third quarter 2010, or $0.33 per diluted share, compared to net loss of $40.02m, or $0.13 loss per diluted

Treakisym is an anticancer agent that exhibits both nitrogen mustard-derived alkylating activity and antimetabolic-like activity. Treakisym is the subject of a licensing agreement concluded between Eisai and SymBio

Amgen and GlaxoSmithKline, who are co-marketing Prolia (denosumab), welcomed the NICE decision. GSK said that the guidance recommends denosumab as a treatment option for the prevention of osteoporotic

InSpire now supports Italian, Spanish, Portuguese, French, German, Dutch, English, Danish, Swedish, Norwegian and Icelandic as well as Malay and Swahili languages, with additional languages to be added

Aoxing Pharma has recently completed construction of chemical synthesis laboratories and pilot-manufacturing plant for the joint venture, which focuses on research, development, manufacturing and marketing of active pharmaceutical

Founded in 2000, Nutritional Alliance is a sales brokerage firm specialising in products intended for drug, food and mass distribution as well as products intended for medical distribution.

ICON, under the partnership with a trusted generic manufacturer has developed both the products following an extensive quality and technical assessment process undertaken by qualified experts in 2005.

Nascobal nasal spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B12 therapy and have no